



## CBSA SPOTLIGHT REVIEW: Vol. I No. IX 12 April – 18 April

### Company Spotlight

- **Accelr8 Technology Corporation** (Denver) announced an agreement with Becton, Dickinson for the BACcel™ rapid bacterial diagnostic system. Becton will fund an 18-month milestone-based project which includes the option to license the technology for product development, manufacturing and, commercialization use for the clinical diagnosis of infectious diseases. BACcel™ rapid diagnostic system may deliver bacterial identification and specific antibiotic susceptibility testing within 8 hours of specimen receipt by eliminating culturing and is based on innovative surface coatings, assay processing, and detection technologies.
- **Corgenix Medical** (Broomfield) received 510(k) clearance by the FDA for their IgG Anti-AtherOx® Test Kit. This new laboratory test detects antibodies in individuals with important autoimmune diseases such as systemic lupus erythematosus and other and lupus-like disorders.
- An important milestone for **Insmed** (Boulder), developer of follow-on biologics and biopharmaceuticals, was achieved in the form of approval from the UK's Medicines and Healthcare products Regulatory Agency to initiate their first clinical study for INS-19, a follow-on biologic product candidate. INS-19, is a recombinant form of human G-CSF, is a follow-on biologic of Neupogen®. Amgen booked 2007 sales of Neupogen® that approached \$900M, and the patent expires in 2013.
- **Keen Ingredients**, based in Louisville, was named “Start-up Company of the Year” by Colorado State University and received a \$15,000 check for the award.. Keen Ingredients specializes in making products derived from quinoa. Founders Laurie Scanlin and Claire Burnett are CSU graduates.

### Financing

- **Lanx** (Broomfield) a medical device company developing and marketing surgical implants and biological products for spinal surgery closed a \$25M Series A financing led by Chicago Growth Partners and also included co-investors Goldman Sachs and Oakwood Medical Investors. The Company currently markets 15 product lines of implants and associated instrumentation for spinal fusion surgery. Lanx is also aggressively developing additional product lines in its core fusion market as well as a broad platform of products in the emerging non-fusion and orthobiologics markets.

### People

- Colorado State University named **Dr. George Seidel**, “Researcher of the Year”. Dr. Seidel, a University Distinguished Professor in the Department of Biomedical Sciences in the College of Veterinary Medicine and Biomedical Sciences works to improve and mainstream embryo-related technologies in livestock production.

### Square Pegs

- Several MBA students are conducting a study on behalf of the Bard Center for Entrepreneurship at the University of Colorado Denver (UCD) Business School for their marketing research course. Their goal is to help the University identify ways that it can better support the Bioscience Community in Colorado through specialized course and program offerings.

Please complete this 10-15 minute survey and know that your responses will be kept confidential and will only be shared at the aggregate level for the purposes of the study and recommendations to the university.

In return for your time and effort the aggregate results of the study will be made available to you.

**Please use this link to access the survey:**

**[www.surveymonkey.com/s.aspx?sm=095p4OMPQQCjTWJJ\\_2ba3oTg\\_3d\\_3d](http://www.surveymonkey.com/s.aspx?sm=095p4OMPQQCjTWJJ_2ba3oTg_3d_3d)**

**The survey will close at Midnight on Sunday April, 27, 2008.**

- **BioBeers** is locked and loaded for **Tuesday 29 April** at our new start time of **6:00pm** to be held at the **Vine St. Pub, 1700 Vine St. Denver 80206**. For more information and to RSVP please visit <http://BioBeers.com>.

## Legislative Update

Attached is last week's legislative report, as provided by our lobbying team, Erin Silver and Danny Tomlinson. Following are highlights:

- Representative Cheri Jahn's HB-1380 passed second reading in the house after substantial debate over the merits of changing the apportionment process of income tax for multi-state corporations. The bill will be heard next on third reading in the House before making its way over to the Senate.
- HB08-1372, the Cord Blood bill, was introduced in the Senate on Wednesday, April 16 and was assigned to the Health and Human Services committee.